- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1550053-02-5] BRD3308
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19618 |
| Brand: | MCE |
| CAS: | 1550053-02-5 |
Overview
| MDL | MFCD30187588 |
|---|---|
| Molecular Weight | 287.29 |
| Molecular Formula | C15H14FN3O2 |
| SMILES | O=C(C)NC1=CC=C(C(NC2=CC=C(F)C=C2N)=O)C=C1 |
Summary
BRD3308 is a highly selective HDAC3 inhibitor with an IC 50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 ( IC 50 of 1.26 μM) or HDAC2 ( IC 50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency [1] [2] [3] .
IC50 & Target
|
HDAC3 54 nM (IC 50 ) |
HDAC3 29 nM (Ki) |
HDAC1 1260 nM (IC 50 ) |
HDAC1 5100 nM (Ki) |
HDAC2 1340 nM (IC 50 ) |
HDAC2 6300 nM (Ki) |
HIV-1
|
In Vitro
BRD3308 (5-30 µM; 6-24 hours) treatment increases HIV-1 expression in the 2D10 cell line
[1]
.
BRD3308 (15 µM; overnight) is able to induce outgrowth of HIV-1 from latently infected cells ex vivo in resting CD4+ T cells
[1]
.
BRD3308 inhibits HDAC1, HDAC2 and HDAC3 with K
i
values of 5.1 μM, 6.3 μM and 29 nM, respectively
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
RT-PCR [1]
| Cell Line: | 2D10 cells |
| Concentration: | 5 µM, 10 µM, 15 µM, or 30 µM |
| Incubation Time: | 6 hours, 12 hours, 18 hours, or 24 hours |
| Result: | An increase in HIV-1 expression was observed. |
In Vivo
BRD3308 (5 mg/kg; intraperitoneal injection; every second day; male Zucker Diabetic Fatty rats) treatment reduces hyperglycaemia and increases insulin secretion in a rat model of type 2 diabetes. At the end of the hyperglycaemic clamp, circulating insulin levels are significantly higher in BRD3308-treated rats. Pancreatic insulin staining and contents are also significantly higher. BRD3308 preserves the functional β-cell mass against glucolipotoxicity in vivo [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Zucker Diabetic Fatty (Obese) rats (6-week-old) [2] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; every second day |
| Result: | Reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 870.20 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.4808 mL | 17.4040 mL | 34.8080 mL |
| 5 mM | 0.6962 mL | 3.4808 mL | 6.9616 mL |
| 10 mM | 0.3481 mL | 1.7404 mL | 3.4808 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.24 mM); Clear solution
References
- [1] Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9(8):e102684.
- [2] Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17(7):703-7.
- [3] Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11(2):363-74.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.